LAG3 and breast carcinoma: A study that specifically included breast cancer patients was a phase I study of LAG525, a monoclonal antibody blocking the binding of LAG-3 to MHC-II in combination with spartalizumab (an anti-PD-1 antibody) in patients with advanced malignancies, which showed durable responses[134].